cefsulodin and Pyelonephritis

cefsulodin has been researched along with Pyelonephritis* in 2 studies

Other Studies

2 other study(ies) available for cefsulodin and Pyelonephritis

Article	Year
Combination therapy of Pseudomonas aeruginosa pyelonephritis in neutropenic mice with human antilipopolysaccharide monoclonal antibody and cefsulodin. The Journal of urology, 1996, Volume: 155, Issue:6 These studies were designed to determine the combined inhibitory effect of a human monoclonal antibody (MAb) and cefsulodin on Pseudomonas aeruginosa renal infection in a neutropenic condition.. Protection against the infection of mice was estimated by survival rate and bacterial numbers in the kidney and blood. Opsonophagocytic assay by human polymorphonuclear neutrophils (PMNs) and fluorescence activated cell sorter (FACS) analysis were also examined.. Treatment of infected mice with MAb combined with a suboptimal dose of cefsulodin prevented the mice from developing pyelonephritis and bacteremia and resulted in a significantly higher survival rate than treatment with either MAb or cefsulodin alone (p < 0.01). When bacteria were preexposed to cefsulodin, a significant enhancement in opsonophagocytic killing with MAb was observed. Fluorescence activated cell sorter analysis suggested that the bacteria incubated with 1/4 minimal inhibitory concentration (MIC) of cefsulodin showed greater binding of MAb to bacteria than the control.. The combination therapy with human antilipopolysaccharide MAb and cefsulodin is useful for P. aeruginosa pyelonephritis in neutropenic hosts. Topics: Animals; Antibodies, Monoclonal; Bacteremia; Cefsulodin; Cephalosporins; Combined Modality Therapy; Female; Flow Cytometry; Humans; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Neutropenia; Neutrophils; Phagocytosis; Pseudomonas Infections; Pyelonephritis	1996
[Clinico-therapeutic and microbiological research on the preparation Monaspor in patients with active pyelonephritis]. Vutreshni bolesti, 1988, Volume: 27, Issue:1 The urinary antiseptic efficacy of cefsulodin (Monaspor--Ciba) was studied in 22 patients with active pyelonephritis. The results were considered very good in 81.8% of the patients with urologic infections caused by P. aeruginosa, P. mirabilis and E. Coli. The drug was well tolerated. The microbiological studies in vitro of the urinary antiseptic efficacy of Monaspor on 575 bacterial strains isolated from patients with active pyelonephritis showed that the antibiotic was most active against Pseudomonas sp., beta-streptococcus, Staph. aureus, P. mirabilis. Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Bacteria; Bacteriuria; Cefsulodin; Drug Evaluation; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pyelonephritis	1988

Article

Year

Combination therapy of Pseudomonas aeruginosa pyelonephritis in neutropenic mice with human antilipopolysaccharide monoclonal antibody and cefsulodin.

The Journal of urology, 1996, Volume: 155, Issue:6

These studies were designed to determine the combined inhibitory effect of a human monoclonal antibody (MAb) and cefsulodin on Pseudomonas aeruginosa renal infection in a neutropenic condition.. Protection against the infection of mice was estimated by survival rate and bacterial numbers in the kidney and blood. Opsonophagocytic assay by human polymorphonuclear neutrophils (PMNs) and fluorescence activated cell sorter (FACS) analysis were also examined.. Treatment of infected mice with MAb combined with a suboptimal dose of cefsulodin prevented the mice from developing pyelonephritis and bacteremia and resulted in a significantly higher survival rate than treatment with either MAb or cefsulodin alone (p < 0.01). When bacteria were preexposed to cefsulodin, a significant enhancement in opsonophagocytic killing with MAb was observed. Fluorescence activated cell sorter analysis suggested that the bacteria incubated with 1/4 minimal inhibitory concentration (MIC) of cefsulodin showed greater binding of MAb to bacteria than the control.. The combination therapy with human antilipopolysaccharide MAb and cefsulodin is useful for P. aeruginosa pyelonephritis in neutropenic hosts.

Topics: Animals; Antibodies, Monoclonal; Bacteremia; Cefsulodin; Cephalosporins; Combined Modality Therapy; Female; Flow Cytometry; Humans; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Neutropenia; Neutrophils; Phagocytosis; Pseudomonas Infections; Pyelonephritis

1996

[Clinico-therapeutic and microbiological research on the preparation Monaspor in patients with active pyelonephritis].

Vutreshni bolesti, 1988, Volume: 27, Issue:1

The urinary antiseptic efficacy of cefsulodin (Monaspor--Ciba) was studied in 22 patients with active pyelonephritis. The results were considered very good in 81.8% of the patients with urologic infections caused by P. aeruginosa, P. mirabilis and E. Coli. The drug was well tolerated. The microbiological studies in vitro of the urinary antiseptic efficacy of Monaspor on 575 bacterial strains isolated from patients with active pyelonephritis showed that the antibiotic was most active against Pseudomonas sp., beta-streptococcus, Staph. aureus, P. mirabilis.

Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Bacteria; Bacteriuria; Cefsulodin; Drug Evaluation; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pyelonephritis

1988